Institutions / Prosight Management, LP
Prosight Management, LP
CIK 1617201 · Institution · as of Dec 31, 2025
Portfolio value
$483.93M
Positions
38
As of
Dec 31, 2025
Top holdings
Dec 31, 2025View all 38 →
| Company | Value | % of portfolio |
|---|---|---|
| PROCEPT BioRobotics Corp | $43.41M | 9.0% |
| Galapagos NV | $35.12M | 7.3% |
| Janux Therapeutics, Inc. | $33.02M | 6.8% |
| Adc Therapeutics SA | $29.93M | 6.2% |
| Kura Oncology, Inc. | $26.28M | 5.4% |
| Meiragtx Hldgs PLC | $25.52M | 5.3% |
| Nektar Therapeutics | $23.45M | 4.8% |
| Veeva Systems Inc | $20.12M | 4.2% |
| ICON plc | $20.04M | 4.1% |
| Boston Scientific Corp | $20.02M | 4.1% |
| Concentra Group Holdings Par | $17.54M | 3.6% |
| Phreesia, Inc. | $16.53M | 3.4% |
| Amicus Therapeutics Inc | $16.38M | 3.4% |
| Select Medical Holdings Corp | $15.37M | 3.2% |
| Syndax Pharmaceuticals Inc | $13.97M | 2.9% |
| Zymeworks Inc. | $13.97M | 2.9% |
| Roivant Sciences Ltd. | $13.61M | 2.8% |
| Crinetics Pharmaceuticals, Inc. | $12.24M | 2.5% |
| Avantor, Inc. | $10.30M | 2.1% |
| Shattuck Labs, Inc.STTK | $8.69M | 1.8% |
| Labcorp Holdings Inc. | $8.66M | 1.8% |
| GeneDx Holdings Corp. | $7.15M | 1.5% |
| Alnylam Pharmaceuticals Inc | $6.80M | 1.4% |
| Immunovant, Inc.IMVT | $6.19M | 1.3% |
| Corbus Pharmaceuticals Holdings, Inc.CRBP | $5.57M | 1.2% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.